In his signature state of the industry report, G. Steven Burrill, CEO, Burrill & Company, will deliver "Biotech 2008 – Life Sciences: A 20/20 Vision to 2020" keynote address. In this presentation he will focus on the state of the biotech industry, highlighting the critical developments in 2007. He will focus on the future, looking forward just over a decade at the projected environment for the industry in the year 2020, and discuss the pathway that will lead us there.

			G. Steven Burrill Chief Executive Officer, Burrill & Company G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Pharmasset (NASDAQ: VRUS) and BioImagene, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board of the Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, Carnegie Mellon, and Duke University, and is an adjunct professor at University of California, San Francisco.